CHEMICARE

A Start Up founded in December 2016 and committed to the discovery and development of orphan drugs for patients affected by calcium-related genetic diseases. ChemICare’s mission is the improvement of the quality of life of patients affected by Tubular Aggregate Myopathy, York Platelet Syndrome and Stormorken Syndrome by the development of a therapy that restores the abnormal intracellular calcium level, a common feature of these three rare diseases.